Cargando…

MACC-1 antibody target therapy suppresses growth and migration of non-small cell lung cancer

Non-small-cell lung cancer (NSCLC) accounts for ~80% of human lung cancers that result in mortalities worldwide. Metastasis-associated in colon cancer-1 (MACC-1) has been demonstrated to be significantly expressed in cases of NSCLC and promotes tumor cell migration and metastasis through transactiva...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Woda, Song, Jianxiang, Wang, Wencai, Zhang, Yajun, Zheng, Shiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865862/
https://www.ncbi.nlm.nih.gov/pubmed/28944826
http://dx.doi.org/10.3892/mmr.2017.7517
_version_ 1783308761191940096
author Shi, Woda
Song, Jianxiang
Wang, Wencai
Zhang, Yajun
Zheng, Shiying
author_facet Shi, Woda
Song, Jianxiang
Wang, Wencai
Zhang, Yajun
Zheng, Shiying
author_sort Shi, Woda
collection PubMed
description Non-small-cell lung cancer (NSCLC) accounts for ~80% of human lung cancers that result in mortalities worldwide. Metastasis-associated in colon cancer-1 (MACC-1) has been demonstrated to be significantly expressed in cases of NSCLC and promotes tumor cell migration and metastasis through transactivation of the metastasis-inducing hepatocyte growth factor/MET proto-gene, receptor tyrosine kinase (HGF/MET) signaling pathway. The present study constructed a chimeric antibody (Chanti-MACC-1) targeting MACC-1 and investigated its potential as a molecular therapeutic target in the treatment of NSCLC therapy. The expression of MACC-1 was detected by reverse transcription-quantitative polymerase chain reaction and western blotting in lung cancer cell lines and tissues. MTT assay was used to detect proliferation of A549 cells treated by Chanti-MACC-1, whereas the functional and regulatory effects of Chanti-MACC-1 in the migration and metastasis of NSCLC cells was investigated by a cell invasion assay. The therapeutic effect and survival time was observed in animal models. The results demonstrated that MACC-1 expression was increased and overexpression of MACC-1 promoted the progression of the cell cycle, significantly promoted NSCLC cell growth and enhanced tumor migration and invasion through the HGF/MET signaling pathway. It was further demonstrated that Chanti-MACC-1 efficiently suppressed MACC-1 expression and significantly inhibited NSCLC cell proliferation, migration and invasion by blocking the HGF/MET signaling pathway. The data revealed that Chanti-MACC-1 was not only beneficial for tumor remission, however additionally contributed to the long-term survival of NSCLC -bearing mice. The findings of the present study indicated that MACC-1 was significantly upregulated and promoted tumor cell growth and migration in NSCLC cells and tissues via transactivation of the metastasis-inducing HGF/MET signaling pathway. However, Chanti-MACC-1significantly inhibited tumor growth and metastasis, which suggested that MACC-1 may be essential for tumor initiation and progression by negatively regulating tumor suppressors.
format Online
Article
Text
id pubmed-5865862
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-58658622018-03-27 MACC-1 antibody target therapy suppresses growth and migration of non-small cell lung cancer Shi, Woda Song, Jianxiang Wang, Wencai Zhang, Yajun Zheng, Shiying Mol Med Rep Articles Non-small-cell lung cancer (NSCLC) accounts for ~80% of human lung cancers that result in mortalities worldwide. Metastasis-associated in colon cancer-1 (MACC-1) has been demonstrated to be significantly expressed in cases of NSCLC and promotes tumor cell migration and metastasis through transactivation of the metastasis-inducing hepatocyte growth factor/MET proto-gene, receptor tyrosine kinase (HGF/MET) signaling pathway. The present study constructed a chimeric antibody (Chanti-MACC-1) targeting MACC-1 and investigated its potential as a molecular therapeutic target in the treatment of NSCLC therapy. The expression of MACC-1 was detected by reverse transcription-quantitative polymerase chain reaction and western blotting in lung cancer cell lines and tissues. MTT assay was used to detect proliferation of A549 cells treated by Chanti-MACC-1, whereas the functional and regulatory effects of Chanti-MACC-1 in the migration and metastasis of NSCLC cells was investigated by a cell invasion assay. The therapeutic effect and survival time was observed in animal models. The results demonstrated that MACC-1 expression was increased and overexpression of MACC-1 promoted the progression of the cell cycle, significantly promoted NSCLC cell growth and enhanced tumor migration and invasion through the HGF/MET signaling pathway. It was further demonstrated that Chanti-MACC-1 efficiently suppressed MACC-1 expression and significantly inhibited NSCLC cell proliferation, migration and invasion by blocking the HGF/MET signaling pathway. The data revealed that Chanti-MACC-1 was not only beneficial for tumor remission, however additionally contributed to the long-term survival of NSCLC -bearing mice. The findings of the present study indicated that MACC-1 was significantly upregulated and promoted tumor cell growth and migration in NSCLC cells and tissues via transactivation of the metastasis-inducing HGF/MET signaling pathway. However, Chanti-MACC-1significantly inhibited tumor growth and metastasis, which suggested that MACC-1 may be essential for tumor initiation and progression by negatively regulating tumor suppressors. D.A. Spandidos 2017-11 2017-09-19 /pmc/articles/PMC5865862/ /pubmed/28944826 http://dx.doi.org/10.3892/mmr.2017.7517 Text en Copyright: © Shi et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Shi, Woda
Song, Jianxiang
Wang, Wencai
Zhang, Yajun
Zheng, Shiying
MACC-1 antibody target therapy suppresses growth and migration of non-small cell lung cancer
title MACC-1 antibody target therapy suppresses growth and migration of non-small cell lung cancer
title_full MACC-1 antibody target therapy suppresses growth and migration of non-small cell lung cancer
title_fullStr MACC-1 antibody target therapy suppresses growth and migration of non-small cell lung cancer
title_full_unstemmed MACC-1 antibody target therapy suppresses growth and migration of non-small cell lung cancer
title_short MACC-1 antibody target therapy suppresses growth and migration of non-small cell lung cancer
title_sort macc-1 antibody target therapy suppresses growth and migration of non-small cell lung cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865862/
https://www.ncbi.nlm.nih.gov/pubmed/28944826
http://dx.doi.org/10.3892/mmr.2017.7517
work_keys_str_mv AT shiwoda macc1antibodytargettherapysuppressesgrowthandmigrationofnonsmallcelllungcancer
AT songjianxiang macc1antibodytargettherapysuppressesgrowthandmigrationofnonsmallcelllungcancer
AT wangwencai macc1antibodytargettherapysuppressesgrowthandmigrationofnonsmallcelllungcancer
AT zhangyajun macc1antibodytargettherapysuppressesgrowthandmigrationofnonsmallcelllungcancer
AT zhengshiying macc1antibodytargettherapysuppressesgrowthandmigrationofnonsmallcelllungcancer